Stock KPTI KARYOPHARM THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Karyopharm Therapeutics Inc.

Equities

KPTI

US48576U1060

Market Closed - Nasdaq
Other stock markets
 21:00:00 01/07/2024 BST 		5-day change 1st Jan Change
0.8155 USD -6.01% Intraday chart for Karyopharm Therapeutics Inc. -25.86% -5.72%
06-28 HC Wainwright Adjusts Price Target on Karyopharm Therapeutics to $7 From $8, Maintains Buy Rating MT
05-08 Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Reports Q1 Revenue $33.1M, vs. Street Est of $34.5M MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Karyopharm Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full Year of 2024
Karyopharm Therapeutics Inc. Announces Presentations in Endometrial Cancer and Myelofibrosis At the 2024 American Society of Clinical Oncology Annual Meeting
Karyopharm Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Karyopharm Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Year 2024
Karyopharm Therapeutics Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Full Year 2023
Karyopharm Therapeutics Says Phase 1 Study of Myelofibrosis Treatment Showed Spleen Volume Reduction Durability
Karyopharm Therapeutics Inc. Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi-Naive Myelofib) Patients
Karyopharm Therapeutics Inc. Announces Resignation of Peter K Honig as Member of the Board of Directors
Karyopharm Therapeutics Inc. Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition
Karyopharm Therapeutics Inc. Reiterates Revenue Guidance for the Full Year 2023
Karyopharm Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Karyopharm, Bristol-Myers Squibb to Assess Mezigdomide With Selinexor for Relapsed, Refractory Multiple Myeloma
Karyopharm Therapeutics Inc. Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD?? Agent CC-92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
Karyopharm Therapeutics Inc. Appoints Zhen Su to Its Board of Directors
Karyopharm Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Karyopharm Therapeutics Inc. Announces Earnings Guidance for the Year 2023
Karyopharm Therapeutics Inc. Announces Presentation of Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer
Top Premarket Gainers
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KPTI Stock
  4. News Karyopharm Therapeutics Inc.
  5. Other languages